DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 39 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 15.57%, DOCS belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
Looking at the Return On Equity, with a value of 18.11%, DOCS belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
The Return On Invested Capital of DOCS (16.83%) is better than 100.00% of its industry peers.
DOCS had an Average Return On Invested Capital over the past 3 years of 12.02%. This is significantly above the industry average of 6.36%.
The 3 year average ROIC (12.02%) for DOCS is below the current ROIC(16.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROIC | 16.83% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
DOCS has a Profit Margin of 33.69%. This is amongst the best in the industry. DOCS outperforms 97.30% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 39.06%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of DOCS has grown nicely.
With an excellent Gross Margin value of 89.94%, DOCS belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DOCS is still creating some value.
DOCS has less shares outstanding than it did 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DOCS has an Altman-Z score of 41.59. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
DOCS has a Altman-Z score of 41.59. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.59 |
ROIC/WACC1.77
WACC9.52%
2.3 Liquidity
A Current Ratio of 7.24 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a Current ratio of 7.24. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has a Quick Ratio of 7.24. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DOCS (7.24) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.94% over the past year.
DOCS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 81.49% yearly.
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.27%.
DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.87% yearly.
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%20.44%
3.2 Future
The Earnings Per Share is expected to grow by 13.57% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.03% on average over the next years. This is quite good.
EPS Next Y22.36%
EPS Next 2Y15.63%
EPS Next 3Y14.08%
EPS Next 5Y13.57%
Revenue Next Year13.9%
Revenue Next 2Y12.11%
Revenue Next 3Y11.3%
Revenue Next 5Y11.03%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.57 indicates a quite expensive valuation of DOCS.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than 75.68% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.29. DOCS is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 43.71, DOCS can be considered very expensive at the moment.
75.68% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.44. DOCS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.57 | ||
| Fwd PE | 43.71 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than the industry average as 67.57% of the companies are valued more expensively.
DOCS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 64.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.69 | ||
| EV/EBITDA | 42.13 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as DOCS's earnings are expected to grow with 14.08% in the coming years.
PEG (NY)2.22
PEG (5Y)N/A
EPS Next 2Y15.63%
EPS Next 3Y14.08%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DOXIMITY INC-CLASS A
NYSE:DOCS (1/21/2025, 8:04:00 PM)
Premarket: 55.81 +0.29 (+0.52%)55.52
+1.8 (+3.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners94.84%
Inst Owner Change-0.05%
Ins Owners2.6%
Ins Owner Change1.34%
Market Cap10.37B
Analysts72.31
Price Target56.33 (1.46%)
Short Float %4.95%
Short Ratio2.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.72%
Min EPS beat(2)15.86%
Max EPS beat(2)23.58%
EPS beat(4)4
Avg EPS beat(4)21.54%
Min EPS beat(4)15.86%
Max EPS beat(4)24.29%
EPS beat(8)8
Avg EPS beat(8)21.05%
EPS beat(12)12
Avg EPS beat(12)30.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.53%
Min Revenue beat(2)3.56%
Max Revenue beat(2)5.51%
Revenue beat(4)3
Avg Revenue beat(4)3.13%
Min Revenue beat(4)-0.57%
Max Revenue beat(4)5.51%
Revenue beat(8)5
Avg Revenue beat(8)1.68%
Revenue beat(12)8
Avg Revenue beat(12)2.18%
Revenue beat(16)10
Avg Revenue beat(16)-0.11%
PT rev (1m)-2.11%
PT rev (3m)61.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.62%
EPS NY rev (1m)0%
EPS NY rev (3m)8.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.77%
Revenue NY rev (1m)-0.51%
Revenue NY rev (3m)3.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.57 | ||
| Fwd PE | 43.71 | ||
| P/S | 20.05 | ||
| P/FCF | 47.69 | ||
| P/OCF | 46.36 | ||
| P/B | 10.78 | ||
| P/tB | 11.94 | ||
| EV/EBITDA | 42.13 |
EPS(TTM)1.12
EY2.02%
EPS(NY)1.27
Fwd EY2.29%
FCF(TTM)1.16
FCFY2.1%
OCF(TTM)1.2
OCFY2.16%
SpS2.77
BVpS5.15
TBVpS4.65
PEG (NY)2.22
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROCE | 20.47% | ||
| ROIC | 16.83% | ||
| ROICexc | 91.88% | ||
| ROICexgc | 189.64% | ||
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% | ||
| FCFM | 42.05% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
ROICexc(3y)87.69%
ROICexc(5y)N/A
ROICexgc(3y)180.49%
ROICexgc(5y)N/A
ROCE(3y)14.62%
ROCE(5y)21.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-48.43%
ROICexc growth 5YN/A
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.02% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.39% | ||
| Profit Quality | 124.83% | ||
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 | ||
| Altman-Z | 41.59 |
F-Score9
WACC9.52%
ROIC/WACC1.77
Cap/Depr(3y)76.9%
Cap/Depr(5y)164.34%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.04%
Profit Quality(3y)121.74%
Profit Quality(5y)186.38%
High Growth Momentum
Growth
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y22.36%
EPS Next 2Y15.63%
EPS Next 3Y14.08%
EPS Next 5Y13.57%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%20.44%
Revenue Next Year13.9%
Revenue Next 2Y12.11%
Revenue Next 3Y11.3%
Revenue Next 5Y11.03%
EBIT growth 1Y41.49%
EBIT growth 3Y47.72%
EBIT growth 5Y90.21%
EBIT Next Year27.96%
EBIT Next 3Y16.39%
EBIT Next 5Y15.44%
FCF growth 1Y44.03%
FCF growth 3Y31.5%
FCF growth 5Y66.11%
OCF growth 1Y40.97%
OCF growth 3Y30.41%
OCF growth 5Y64.46%